جستجوی مقالات مرتبط با کلیدواژه "میلوم مالتیپل" در نشریات گروه "پزشکی"

Telomerase-targeted therapy for cancer has received great attention because telomerase is expressed in almost all cancer cells but is inactive in most normal somatic cells. This study aimed to investigate the effects of telomerase inhibitor MST-312, a chemically modified derivative of epigallocatechin gallate (EGCG), on apoptosis of myeloma cell line U266.
In an Experimental study, U266 cells were treated with different concentrations of MST-312 at different times; then, cell viability by trypan blue exclusion assay, cell metabolic activity by MTT assay, and cell apoptosis by Annexin V Apoptosis Detection Kit were measured. To further investigate apoptosis, BAX and BCL2 gene expression of the treated cells was investigated by the quantitative Real-Time PCR.
MST-312 exerted a dose-dependent short-term cytotoxic effect on myeloma cells. Over 50% decrease in the viability of treated cells was seen in 8 μM concentration of MST-312 within 48 h. The cytotoxic effect of MST-312 was concentration-dependent, with approximately 25, 46, and 62% reduction in metabolic activity after 48 h exposure to 2, 4, and 8 μM of MST-312, respectively. Gene expression analysis showed downregulation of antiapoptotic gene Bcl-2 and upregulation of apoptopic gene BAX.
Inhibition of telomerase activity by MST-312 represents a novel treatment strategy for Multiple Myeloma cancer.

Hematologic malignancies are caused by impaired proliferation of blood cells. These diseases like some other systemic disorders have some manifestations in the oral cavity. The purpose of this study is to review the literature on oral signs and symptoms of malignant hematologic disorders in order to familiarize the dentists with these manifestations and assisting in early detection of the diseases. Subjects and This study is based on a review of oral manifestations of hematological malignancies on reliable scientific databases. In this study “Oral manifestation”, “Lymphoma”, “Leukemia” and “Multiple myeloma” (single or double) were employed as keywords. Several papers on oral manifestations of hematologic malignancies (including leukemia, lymphoma and multiple myeloma) are available. Their results show that the oral signs and symptoms caused by these malignancies (e.g. pallor of the mucosa, gingival enlargement, bleeding, trismus, and bone changes) can be important evidence in identifying them and even in some cases may be the first sign of illness. Oral signs and symptoms can be seen in a variety of hematologic malignancies, which even in some cases are the first signs of disease. So the dentist can play an important role in early detection and referral of patients to the relevant specialists.